Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, focusing on severe respiratory conditions. Its lead candidate, verekitug, is a monoclonal antibody targeting the TSLP receptor to treat asthma, CRSwNP, and COPD. The company aims to improve clinical outcomes with extended dosing intervals, addressing unmet needs in immune-mediated diseases through innovative biologics.
This description was generated via AI from an annual report. Updated about 1 year ago.